

Newsletter

# Klinische Studien

Liebe Kolleginnen und Kollegen,  
in unserem Update ‚Klinische Studien‘ stellen wir Ihnen regelmäßig ausgewählte, hämatologische und onkologische, aktuell rekrutierende Studien vor, die am UKSH angeboten werden. Gleichzeitig möchten wir zukünftig diesen Newsletter nutzen, um auch die Studien unser Partner im Netzwerk darzustellen und somit das Versorgungsgebiet Schleswig-Holstein bestmöglich abzubilden. Damit möchten wir die Rekrutierung Ihrer und unserer Studien unterstützen und das Studienangebot im Netzwerk erweitern.

**Kontakt UCCSH:** Dr. Christina Schwitlick ✉ [christina.schwitlick@uksh.de](mailto:christina.schwitlick@uksh.de)

Eine Übersicht über alle derzeit rekrutierenden Studien finden Sie unter <https://www.quickqueck.de>

new

## chronische lymphatische Leukämie

**Abbvie M20-356 Phase II** A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring Chronic Lymphocytic Leukemia

**Indikation** Chronic lymphocytic leukemia (CLL)

**Campus Kiel** Dr. med. Matthias Ritgen ✉ [matthias.ritgen@uksh.de](mailto:matthias.ritgen@uksh.de) ☎ 0431 500-22 511

## nicht-kleinzelliges Lungenkarzinom

**KEYVIBE-007 Phase III** Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer

**Indikation** Stage IV squamous or non-squamous NSCLC; no prior systemic treatment for metastatic NSCLC

**Campus Lübeck** Dr. med. Sabine Bohnet ✉ [sabine.bohnet@uksh.de](mailto:sabine.bohnet@uksh.de) ☎ 0451 500-45 002

## fortgeschrittene hämatologische Malignome

**NIMBLE Phase I/II** A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

**Indikation** acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL)

**Campus Kiel** Prof. Dr. Claudia Baldus ✉ [claudia.baldus@uksh.de](mailto:claudia.baldus@uksh.de) ☎ 0431 500-22 501

## Kastrationsresistentes Prostatakarzinom

**CONTACT-02 Phase III** A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

**Indikation** adenocarcinoma of the prostate, metastatic, Surgical or medical castration

**Campus Lübeck** Prof. Dr. Axel Merseburger ✉ [axel.merseburger@uksh.de](mailto:axel.merseburger@uksh.de) ☎ 0451 500-43 699

### Multiples Myelom

**M13-494 Phase III** A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma

**Indikation** t(11;14)-positive Relapsed or Refractory Multiple Myeloma

**Campus Kiel** Dr. med. Natalie Schub [✉ natalie.schub@uksh.de](mailto:natalie.schub@uksh.de) ☎ 0431 500-22751

### Urothelkarzinom

**EV-302 (SeaGen) Phase III** An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

**Indikation** unresectable locally advanced or metastatic urothelial carcinoma

**Campus Lübeck** Prof. Dr. Axel Merseburger [✉ axel.merseburger@uksh.de](mailto:axel.merseburger@uksh.de) ☎ 0451 500-43699

### Endometriumkarzinom

**Keynote- B21 Phase III** A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent

**Indikation** new diagnosis of Endometrial Carcinoma or Carcinosarcoma (Mixed Mullerian Tumor); has undergone curative intent surgery that included hysterectomy and bilateral salpingo-oophorectomy

**Campus Lübeck** PD Dr. Lars Hanker [✉ lars.hanker@uksh.de](mailto:lars.hanker@uksh.de) ☎ 0451 500-41700

### Adenokarzinom des gastroösophagealen Übergangs

**CARDIA Trial Chirurgische Therapie** Chirurgische Therapie für das Adenokarzinom des gastroösophagealen Überganges (AEG Typ II): Transthorakale Ösophagektomie vs. Transhiatal erweiterte Gastrektomie.

**Indikation** nicht-metastasiertes Adenokarzinom AEG Typ II

**Campus Lübeck** Prof. Dr. Jens Höppner [✉ jens.hoepfner@uksh.de](mailto:jens.hoepfner@uksh.de) ☎ 0451 500-40136

### Multiples Myelom

**MajesTEC-3 Phase III** A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (Dvd) in Participants with Relapsed or Refractory Multiple Myeloma

**Indikation** Relapsed or Refractory Multiple Myeloma

**Campus Kiel** Dr. med. Natalie Schub [✉ natalie.schub@uksh.de](mailto:natalie.schub@uksh.de) ☎ 0431 500-22751

### HER-2 negativer Brustkrebs

**EPIK-B5 Phase III** A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

**Indikation** Hormone receptor positive, HER2-negative advanced breast cancer

**Campus Lübeck** PD Dr. Maggie Banys-Paluchowski [✉ maggie.banys-paluchowski@uksh.de](mailto:maggie.banys-paluchowski@uksh.de) ☎ 0451 500-41700

### Diffus großzelliges B-Zell-Lymphom

**frontMIND Phase III** A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

**Indikation** Indikation: Newly-diagnosed Diffuse Large B-cell Lymphoma

**Campus Lübeck** PD Dr. Niklas Gebauer [✉ niklas.gebauer@uksh.de](mailto:niklas.gebauer@uksh.de) ☎ 0451 500-44355